Skip to main content

Table 2 Maintenance therapy and survival after CR/nCR

From: Long-term outcome and relapse patterns in Ewing sarcoma patients with extensive lung/pleural metastases after a complete response to systemic therapy

Baseline characteristics

From meta to CR/nCR

Time from CR/nCR to the following conditions (months)

No

Age

Time to meta

Baseline metastasesa

Regimen before CR/nCR

Time to CR/nCR

WLI

Maintenance therapy

Status at last follow-upb

Last follow up

Local recurrence or metastatis

Death

1

8y

8.9

L

AVI

1.7

Yes

VI

DOD1

-

12.4

30.0

2

21y

10.3

P

AVI

3.6

Yes

CTX + Celecoxib

DOD2

-

6.2

37.5

3

21y

11.7

L

AVI

4.0

Yes

AVI

NED

38.8

-

-

4

23y

15.2

L

AVI

6.3

Yes

VI

AWD

33.4

3.5

-

5

36y

41.7

L

AVI

7.0

Yes

AVI

AWD

32.3

17.2

-

6

12y

8.5

L + P

AVI

5.7

Yes

A

DOD2

-

2.6

22.0

7

18y

21.7

L + P

AVI

5.8

Yes

VI + olaparib

DOD2

-

6.6

14.4

8

8y

18.7

L

AVI

2.8

Yes

A

AWD

33.0

6.5

-

9

39y

29.9

L

AVI

4.2

Yes

AVI

AWD

28.6

15.9

-

10

8y

0.0

L

VDC-IE

3.1

No

CTX + Celecoxib

AWD

63.8

31.5

-

11y

14.7

L

AVI

7.5

Yes

A

AWD

24.8

22.8

-

11

13y

0.0

L

VDC-IE

6.2

No

No

DOD1

-

7.5

26.4

15y

23.5

L

VIT

3.5

No

No

DOD1

-

4.1

5.6

12

4y

0.0

L

VDC-IE

4.1

No

No

AWD

57.7

12.9

-

6y

17.1

L

IE-VI

6.5

No

CTX + Celecoxib

AWD

38.3

17.8

-

8y

41.4

L

VIT

9.8

No

No

AWD

10.7

8.7

-

13

24y

0.0

L

VDC-IE

5.4

No

No

DOD1

-

9.3

16.8

14

28y

15.3

L

AVI

4.6

Yes

VIT

DOD1

-

2.4

17.2

15

30y

19.7

L

AVI

6.4

Yes

AVI

NED

33.2

-

-

16

8y

18.9

L

AVI

4.1

Yes

VI

DOD2

-

2.0

12.8

17

5y

0.0

P

VDC-IE

6.2

Yes

CTX + Celecoxib

NED

35.4

-

-

  1. Time to meta: From initial diagnosis of EWS to the experience of ExL/PMeta (months)
  2. Time to CR/nCR: From the delivery of first dose of chemotherapy drug to CR/nCR (months)
  3. WLI Whole lung irradiation, AVI Anlotinib + Vincristine + Irinotecan, VIT Vincristine + vincristine + irinotecan, VDC-IE Vincristine + doxorubicin + cyclophosphamide / ifosfamide + etoposide, A Anlotinib, VI Vincristine + irinotecan, NED None evidence of disease, AWD Alive with disease, DOD Dead of disease
  4. aL = only lung metastases only; P = only pleural effusion/nodules; L + P = both lung and pleural effusion/nodules
  5. bDOD1 Died of lung/pleural metastases, DOD2 Died of other reasons regarding to EWS